Inhibition and reversal of denervation-induced atrophy by the <i>β</i>-agonist growth promoter, clenbuterol

Maltin, C A; Reeds, Peter J.; Delday, Margaret Inkster; Hay, Susan M.; Smith, F. G. Walton; Lobley, G. E.

doi:10.1007/bf01117104

Cited by 67 publications

(32 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several of the models, both the VPAC1R and VPAC2R agonists were evaluated even though only the VPAC2R agonist demonstrated efficacy in the muscle bath experiment to evaluate whether activation of VPAC1R had a role in modifying skeletal muscle mass via activation at a site distant from skeletal muscle (indirect effect). In addition, treatment with the ␤ 2 -adrenergic agonist clenbuterol was included as a positive control because clenbuterol has been previously demonstrated to inhibit the loss of skeletal muscle mass resulting from atrophy in mice and rats (30).…”

Section: Resultsmentioning

confidence: 99%

“…For example, atrophy in both rodents and humans, induced by a variety of means, results in similar changes in muscle anatomy, cross-sectional area, function, fiber-type switching, contractile protein expression, and histology (2). In addition, several agents have been demonstrated to modulate skeletal muscle atrophy, induced by a variety of methods, in rodents and in humans, including anabolic steroids, growth hormone, insulin-like growth factor I, and ␤-adrenergic agonists (18,29,30,32,35,42).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force

Hinkle¹,

Donnelly²,

Cody³

et al. 2005

Journal of Applied Physiology

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force

Hinkle¹,

Donnelly²,

Cody³

et al. 2005

Journal of Applied Physiology

View full text Add to dashboard Cite

show abstract

“…8 The growth-promoting effect of clen is not confined to normal skeletal muscle but is also evident in certain states of altered physiology and even pathology. For example, it has been shown to inhibit and reverse denervation 23 and disuse 24 atrophy. It also induces beneficial changes in the mdx mouse.…”

Section: Discussionmentioning

confidence: 99%

Clenbuterol Increases Stroke Power and Contractile Speed of Skeletal Muscle for Cardiac Assist

et al. 1999

View full text Add to dashboard Cite

Background-Skeletal muscle assist (SMA) may be limited by loss of power, slowing of contraction and relaxation, and atrophy of the transformed latissimus dorsi muscle (LD). Clenbuterol (clen), a ␤ 2 -adrenergic receptor agonist, was used to improve the performance of trained skeletal muscle in sheep. Methods and Results-The following 4 groups were used: A (nϭ6), untrained controls; B (nϭ6), left LD progressively transformed toward a slow-twitch and fatigue-resistant phenotype by electrical stimulation over 12 weeks (2.5 to 5 V, 240-sec pulse duration, 35 Hz, 3 to 6 pulses per burst, and up to 40 bursts per minute); C (nϭ6), clen-treated (0.5 mg/kg SC) for 12 weeks; and D (nϭ6), clenϩtrained. In a terminal experiment, the mobilized LD was wrapped around a rubber aorta of a mock circulation and stimulated to contract 40 times per minute. Group A had an initial mean pressure augmentation (⌬P) of 24.6 mm Hg and stroke power of 2.28 W/kg, but both fell to Ͻ20% of their original values by 15 minutes because of fatigue (PϽ0.005). Group B was fatigue-resistant, with a ⌬P and stroke power at 60 minutes of 13 mm Hg (70% of initial) and 0.34 W/kg (39% of initial), respectively. The performance of group C was similar to that of controls. In group D, however, the muscles were stronger at all time points than in B, with a ⌬P of 23 mm Hg and stroke power of 2.66 W/kg at 60 minutes (PϽ0.01). The speeds of contraction (ϩdP/dt:⌬P) and relaxation (ϪdP/dt:⌬P) were significantly greater in group D than B.Protein analyses showed group D to have only a trend toward greater abundance of the fast isoforms of myosin heavy chain and sarcoplasmic reticulum Ca

show abstract

“…Clenbuterol treatment reduced the loss of wet weight and of protein content and also increased the cross-sectional area of denervated solei. Data reported by Maltin et al (6) indicate that clenbuterol not only inhibits but also partially reverses denervation-induced atrophy of rat soleus muscle. This was evident from measurements of both muscle protein content and fiber cross-sectional areas.…”

Section: Introductionmentioning

confidence: 83%

Effect of salbutamol on innervated and denervated rat soleus muscle

Šoić-Vranić

Bobinac

Bajek

et al. 2005

Braz J Med Biol Res

View full text Add to dashboard Cite

The objective of the present investigation was to perform a 14-day time-course study of treatment with salbutamol, a ß 2 adrenoceptor agonist, on rat soleus muscle in order to assess fiber type selectivity in the hypertrophic response and fiber type composition. Male Wistar rats were divided into four groups: control (N = 10), treated with salbutamol (N = 30), denervated (N = 30), and treated with salbutamol after denervation (N = 30). Salbutamol was injected intraperitoneally in the rats of the 2nd and 4th groups at a concentration of 0.3 mg/kg twice a day for 2 weeks. The muscles were denervated using the crush method with pean. The animals were sacrificed 3, 6, 9, 12, and 14 days after treatment. Frozen cross-sections of soleus muscle were stained for myosin ATPase, pH 9.4. Cross-sectional area and percent of muscle fibers were analyzed morphometrically by computerized image analysis. Treatment with salbutamol induced hypertrophy of all fiber types and a higher percentage of type II fibers (21%) in the healthy rat soleus muscle. Denervation caused marked atrophy of all fibers and conversion from type I to type II muscle fibers. Denervated muscles treated with salbutamol showed a significantly larger crosssectional area of type I muscle fibers, 28.2% compared to the denervated untreated muscle. Moreover, the number of type I fibers was increased. These results indicate that administration of salbutamol is able to induce changes in cross-sectional area and fiber type distribution in the early phase of treatment. Since denervation-induced atrophy and conversion from type I to type II fibers were improved by salbutamol treatment we propose that salbutamol, like other ß 2 adrenoceptor agonists, may have a therapeutic potential in improving the condition of skeletal muscle after denervation.

show abstract

Inhibition and reversal of denervation-induced atrophy by the β-agonist growth promoter, clenbuterol

Cited by 67 publications

References 7 publications

Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force

Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force

Clenbuterol Increases Stroke Power and Contractile Speed of Skeletal Muscle for Cardiac Assist

Effect of salbutamol on innervated and denervated rat soleus muscle

Contact Info

Product

Resources

About